Incete

Incyte is a global biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics in oncology, inflammation, and autoimmunity. The company is best known for its flagship product, Jakafi (ruxolitinib), which is approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. Incyte has also expanded into dermatology with Opzelura, a topical JAK inhibitor for atopic dermatitis and vitiligo. Their robust pipeline includes a diverse range of small molecules and monoclonal antibodies targeting various pathways in hematology and solid tumors. Headquartered in Wilmington, Delaware, Incyte maintains a strong commitment to scientific innovation and clinical research to address significant unmet medical needs.